Caisse DE Depot ET Placement DU Quebec Purchases 552,590 Shares of Halozyme Therapeutics, Inc. $HALO

Key Points

• Caisse DE Depot ET Placement DU Quebec increased its stake in Halozyme Therapeutics by 154.5%, acquiring a total of 910,169 shares valued at $58 million.
• Halozyme Therapeutics reported $1.54 EPS for the last quarter, exceeding analysts' expectations, and its revenue increased by 40.8% year-over-year.
• Analysts have varied opinions on HALO shares, with target prices ranging from $47 to $75, resulting in a consensus rating of "Hold" with a target of $67.11.

Caisse DE Depot ET Placement DU Quebec increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 154.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 910,169 shares of the biopharmaceutical company's stock after purchasing an additional 552,590 shares during the quarter. Caisse DE Depot ET Placement DU Quebec owned approximately 0.74% of Halozyme Therapeutics worth $58,078,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Penserra Capital Management LLC acquired a new position in Halozyme Therapeutics during the first quarter worth $125,000. Bessemer Group Inc. boosted its holdings in Halozyme Therapeutics by 62.9% during the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 207 shares during the last quarter. D. E. Shaw & Co. Inc. boosted its holdings in Halozyme Therapeutics by 171.2% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock worth $39,750,000 after purchasing an additional 524,802 shares during the last quarter. Fifth Third Bancorp raised its position in Halozyme Therapeutics by 29.4% during the first quarter. Fifth Third Bancorp now owns 10,017 shares of the biopharmaceutical company's stock worth $639,000 after acquiring an additional 2,276 shares in the last quarter. Finally, GAMMA Investing LLC raised its position in Halozyme Therapeutics by 199.0% during the first quarter. GAMMA Investing LLC now owns 2,802 shares of the biopharmaceutical company's stock worth $179,000 after acquiring an additional 1,865 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Halozyme Therapeutics Stock Performance

Shares of HALO stock traded up $0.34 on Friday, hitting $73.15. The company's stock had a trading volume of 1,163,957 shares, compared to its average volume of 2,254,612. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. The stock's 50 day moving average is $60.68 and its 200-day moving average is $59.28. Halozyme Therapeutics, Inc. has a fifty-two week low of $42.01 and a fifty-two week high of $74.07. The company has a market capitalization of $8.56 billion, a PE ratio of 16.74, a PEG ratio of 0.42 and a beta of 1.17.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, beating the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The business had revenue of $325.72 million for the quarter, compared to the consensus estimate of $282.66 million. During the same period in the prior year, the company posted $0.91 earnings per share. Halozyme Therapeutics's revenue was up 40.8% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Equities research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $63.51, for a total value of $1,270,200.00. Following the transaction, the chief executive officer directly owned 733,719 shares in the company, valued at approximately $46,598,493.69. This represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold 80,000 shares of company stock valued at $4,532,600 in the last 90 days. Corporate insiders own 2.40% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on HALO shares. Benchmark lowered shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 7th. JMP Securities upped their price target on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a "market outperform" rating in a research report on Wednesday, August 6th. HC Wainwright upped their price target on shares of Halozyme Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research report on Wednesday, August 6th. JPMorgan Chase & Co. upped their price target on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a "neutral" rating in a research report on Thursday, August 7th. Finally, Leerink Partners lowered shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price objective on the stock. in a research report on Tuesday, May 13th. Four analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $67.11.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.